Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Unknown 5Completed 3Terminated 2Recruiting 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Older Patients 1

Interventions

Cisplatin 10Gemcitabine 7Fluorouracil 7Carboplatin 7Capecitabine 7venetoclax 5Oxaliplatin 5Cyclophosphamide 4sintilimab 3Radiotherapy 3Neoadjuvant Therapy 3Dexamethasone 3Bevacizumab 3Azacitidine 3130-nm albumin-bound paclitaxel 3trametinib 2regorafenib 2pembrolizumab 2nimotuzumab 2fludarabine 2disitamab vedotin 2daratumumab 2dabrafenib 2camrelizumab 2blinatumomab 2apatinib 2Trastuzumab 2Temozolomide 2Radiotherapy, Intensity-Modulated 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Not yet recruiting × Busulfan × Clear all
NCT07052422 2025-07-04

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Nanfang Hospital, Southern Medical University

Phase 2/3 Not yet recruiting
160 enrolled
Other neoplasm

Older Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡